Wedbush Analysts Decrease Earnings Estimates for Foghorn Therapeutics Inc. (NASDAQ:FHTX)

Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Rating) – Stock analysts at Wedbush reduced their Q2 2023 earnings per share estimates for shares of Foghorn Therapeutics in a report issued on Tuesday, May 9th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($0.74) per share for the quarter, down from their […]

Related Keywords

United States ,America , ,Jpmorgan Chase Co ,Geode Capital Management ,Tower Research Capital ,Charles Schwab Investment Management Inc ,Nasdaq ,Foghorn Therapeutics Inc ,Foghorn Therapeutics ,Get Rating ,Foghorn Therapeutic ,Schwab Investment Management ,Street Corp ,Capital Management ,Research Capital ,Therapeutics Inc ,Gene Traffic Control ,Foghorn Therapeutics Daily ,Nasdaq Fhtx ,Fhtx ,Medical ,Earnings Estimates ,Wedbush ,